There are currently 92 ongoing clinical trials involving Neuropathy
Of the 92 trials,38 trials are in Phase II
Furthermore, 22 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Neuropathy, a central nervous system disorder. The highest number of ongoing clinical trials involving Neuropathy is conducted in Europe. North America and Asia-pacific are among some of the other prominent regions involved in Neuropathy-related drug trials.
Argenx SE: The leading ongoing Neuropathy related clinical trials sponsor
Argenx SE, the Netherlands-based human antibodies developer, is the top sponsor for Neuropathy-related ongoing clinical trials.
Aarhus University, Winsantor Inc, Academic Medical Center, and Odense University Hospital are a few other notable sponsors involving Neuropathy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Neuropathy
Methycobal (mecobalamin), Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga), and Human normal immunoglobulin (Venilon/ GGS-MPA) are among the key marketeddrugs involving Neuropathy.
Methycobal (mecobalamin) is a peripheral nerve repair agent and anti-anemia agent. It is formulated as tablet and fine granules for oral administration and injection for intramuscular or intravenous use. Methycobal Tablet is indicated for the treatment of peripheral neuropathy and injection is used for the treatment of peripheral neuropathy and megaloblastic anemia. Mecobalamin acts to repair damaged nerve, relieve pain and numbness and improve sensory disturbances and dyskinesia. It also promotes nucleic acid synthesis in bone marrow and promotes the maturation and division of erythroblasts. Methycobal was first approved in 1979 and is sold in China by Eisai China Inc, India by Wockhardt Ltd, Japan by Eisai Co Ltd, and South Korea by Daewoong Pharmaceutical Co Ltd.
Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) is an immune sera preparation first approved in 1996. Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. It is formulated as injectable solution for intravenous route of administration. Human normal immunoglobulin is used for the treatment of primary immunodeficiency syndromes such as congenital agammaglobulinemia and hypogammaglobulinemia, severe combined immunodeficiencies, Wiskott Aldrich syndrome, chronic lymphatic leukemia with severe secondary hypogammaglobulinemia and recurrent infections and children with congenital AIDS who have repeated bacterial infections. Panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment. Human normal immunoglobulin is marketed globally including the US, the UK, Australia, France, Germany, and Russia by several prominent companies including Octapharma USA Inc, Pfizer Inc, and PT Harsen Laboratories.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer